Baseline characteristics of 74 patients with blast phase evolving from prior myeloproliferative neoplasm (MPN)
| Baseline characteristics at blast phase . | No. (%) . | One-year survival, % . | Median survival, mo . | P . |
|---|---|---|---|---|
| Diagnosis | NS | |||
| Primary myelofibrosis | 36 (49) | 28 | 3 | |
| Secondary myelofibrosis | 7 (9) | 14 | 5 | |
| Polycythemia vera | 18 (24) | 28 | 7 | |
| Essential thrombocytosis | 7 (9) | 29 | 4 | |
| Chronic myeloproliferative neoplasm, unclassifiable | 6 (8) | 40 | 8 | |
| Time from MPN diagnosis to blast phase | NS | |||
| Less than 5 y | 39 (53) | 29 | 5 | |
| 5 y or more | 35 (47) | 26 | 5 | |
| Age | .002 | |||
| Less than 60 y | 22 (30) | 48 | 10 | |
| 60 y or more | 52 (70) | 18 | 4 | |
| Sex | NS | |||
| Male | 49 (66) | 33 | 4 | |
| Female | 25 (34) | 17 | 5 | |
| Zubrod Performance Status | < .001 | |||
| 0 or 1 | 54 (75) | 33 | 7 | |
| 2 or more | 18 (25) | 10 | 1.5 | |
| Number of MPN therapies | NS | |||
| Less than 3 | 48 (65) | 30 | 6 | |
| 3 or more | 26 (35) | 23 | 2.5 | |
| Prior hydroxyurea | NS | |||
| Yes | 54 (73) | 23 | 4 | |
| No | 20 (27) | 38 | 8 | |
| Prior alkylating agents | NS | |||
| Yes | 11 (15) | 32 | 8 | |
| No | 63 (85) | 26 | 4 | |
| Prior radioactive phosphorus | NS | |||
| Yes | 3 (4) | 33 | 7 | |
| No | 71 (96) | 27 | 5 | |
| Prior erythropoietin | NS | |||
| Yes | 20 (27) | 22 | 4 | |
| No | 54 (73) | 29 | 5 | |
| Hemoglobin | NS | |||
| Less than 100 g/L | 56 (77) | 28 | 4 | |
| 100 g/L or more | 17 (23) | 24 | 5 | |
| White cell count | NS | |||
| Less than 11 × 109/L | 33 (45) | 30 | 5 | |
| 11 × 109/L or more | 40 (55) | 24 | 4 | |
| Platelet count | NS | |||
| Less than 100 × 109/L | 46 (63) | 24 | 5 | |
| 100 × 109/L or more | 27 (37) | 31 | 7 | |
| Peripheral blood blasts | .03 (< vs ≥ 20%) | |||
| Less than 20% | 25 (34) | 53 | 13 | |
| 20% to 49% | 33 (45) | 18 | 4 | |
| 50% or more | 3 (21) | 0 | 4 | |
| Marrow blasts | .16 (< vs ≥ 50%) | |||
| Less than 20% | 14 (20) | 36 | 5 | |
| 20 to 49% | 42 (60) | 29 | 6 | |
| 50% or more | 14 (20) | 17 | 2.5 | |
| Spleen | .04 (splenectomy vs all others) | |||
| Not palpable | 29 (40) | 22 | 5 | |
| 1 to 5 cm below left costal margin | 7 (10) | 40 | 8 | |
| More than 5 cm below left costal margin | 21 (29) | 41 | 5 | |
| Prior splenectomy | 15 (21) | 13 | 2 | |
| Genetics | .02 (abnormal chromosome 17 vs all others) | |||
| Deletion of 20q | 3 (5) | 67 | 32 | |
| Diploid karyotype | 16 (28) | 38 | 7 | |
| Trisomy 8 and other noncomplex abnormalities | 11 (19) | 29 | 7 | |
| Abnormal chromosome 5 or 7, or complex (≥3) abnormal | 17 (29) | 35 | 5 | |
| Abnormal chromosome 17 | 11 (19) | 0 | 3.5 | |
| JAK2 MPN phase | NS | |||
| Positive | 12 (60) | 29 | 5 | |
| Negative | 8 (40) | 0 | 2 | |
| JAK2 blast phase | NS | |||
| Positive | 16 (43) | 50 | 5 | |
| Negative | 21 (57) | 30 | 7 | |
| Treatment | <.001 | |||
| Treated for blast phase | 55 (74) | 35 | 7 | |
| Supportive care only | 19 (26) | 5 | 1.5 |
| Baseline characteristics at blast phase . | No. (%) . | One-year survival, % . | Median survival, mo . | P . |
|---|---|---|---|---|
| Diagnosis | NS | |||
| Primary myelofibrosis | 36 (49) | 28 | 3 | |
| Secondary myelofibrosis | 7 (9) | 14 | 5 | |
| Polycythemia vera | 18 (24) | 28 | 7 | |
| Essential thrombocytosis | 7 (9) | 29 | 4 | |
| Chronic myeloproliferative neoplasm, unclassifiable | 6 (8) | 40 | 8 | |
| Time from MPN diagnosis to blast phase | NS | |||
| Less than 5 y | 39 (53) | 29 | 5 | |
| 5 y or more | 35 (47) | 26 | 5 | |
| Age | .002 | |||
| Less than 60 y | 22 (30) | 48 | 10 | |
| 60 y or more | 52 (70) | 18 | 4 | |
| Sex | NS | |||
| Male | 49 (66) | 33 | 4 | |
| Female | 25 (34) | 17 | 5 | |
| Zubrod Performance Status | < .001 | |||
| 0 or 1 | 54 (75) | 33 | 7 | |
| 2 or more | 18 (25) | 10 | 1.5 | |
| Number of MPN therapies | NS | |||
| Less than 3 | 48 (65) | 30 | 6 | |
| 3 or more | 26 (35) | 23 | 2.5 | |
| Prior hydroxyurea | NS | |||
| Yes | 54 (73) | 23 | 4 | |
| No | 20 (27) | 38 | 8 | |
| Prior alkylating agents | NS | |||
| Yes | 11 (15) | 32 | 8 | |
| No | 63 (85) | 26 | 4 | |
| Prior radioactive phosphorus | NS | |||
| Yes | 3 (4) | 33 | 7 | |
| No | 71 (96) | 27 | 5 | |
| Prior erythropoietin | NS | |||
| Yes | 20 (27) | 22 | 4 | |
| No | 54 (73) | 29 | 5 | |
| Hemoglobin | NS | |||
| Less than 100 g/L | 56 (77) | 28 | 4 | |
| 100 g/L or more | 17 (23) | 24 | 5 | |
| White cell count | NS | |||
| Less than 11 × 109/L | 33 (45) | 30 | 5 | |
| 11 × 109/L or more | 40 (55) | 24 | 4 | |
| Platelet count | NS | |||
| Less than 100 × 109/L | 46 (63) | 24 | 5 | |
| 100 × 109/L or more | 27 (37) | 31 | 7 | |
| Peripheral blood blasts | .03 (< vs ≥ 20%) | |||
| Less than 20% | 25 (34) | 53 | 13 | |
| 20% to 49% | 33 (45) | 18 | 4 | |
| 50% or more | 3 (21) | 0 | 4 | |
| Marrow blasts | .16 (< vs ≥ 50%) | |||
| Less than 20% | 14 (20) | 36 | 5 | |
| 20 to 49% | 42 (60) | 29 | 6 | |
| 50% or more | 14 (20) | 17 | 2.5 | |
| Spleen | .04 (splenectomy vs all others) | |||
| Not palpable | 29 (40) | 22 | 5 | |
| 1 to 5 cm below left costal margin | 7 (10) | 40 | 8 | |
| More than 5 cm below left costal margin | 21 (29) | 41 | 5 | |
| Prior splenectomy | 15 (21) | 13 | 2 | |
| Genetics | .02 (abnormal chromosome 17 vs all others) | |||
| Deletion of 20q | 3 (5) | 67 | 32 | |
| Diploid karyotype | 16 (28) | 38 | 7 | |
| Trisomy 8 and other noncomplex abnormalities | 11 (19) | 29 | 7 | |
| Abnormal chromosome 5 or 7, or complex (≥3) abnormal | 17 (29) | 35 | 5 | |
| Abnormal chromosome 17 | 11 (19) | 0 | 3.5 | |
| JAK2 MPN phase | NS | |||
| Positive | 12 (60) | 29 | 5 | |
| Negative | 8 (40) | 0 | 2 | |
| JAK2 blast phase | NS | |||
| Positive | 16 (43) | 50 | 5 | |
| Negative | 21 (57) | 30 | 7 | |
| Treatment | <.001 | |||
| Treated for blast phase | 55 (74) | 35 | 7 | |
| Supportive care only | 19 (26) | 5 | 1.5 |
Percentages are the proportion of patients with known characteristics.
NS indicates not significant.